Pregabalin in neuropathic pain related to DPN, cancer and back pain: Analysis of a 6-week observational study

Open Pain Journal

Volumn 5, Issue 1, 2012, Pages 1-11

  Toelle, Thomas R ^a   Varvara, Roxana ^b   Nimour, Meryem ^b   Emir, Birol ^c   Brasser, Matthias ^c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c PFIZER INC   (United States)

Author keywords

Back pain; Cancer; DPN; Neuropathic pain; Observational; Pregabalin

Indexed keywords

PREGABALIN;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BACKACHE; CANCER PAIN; CONTROLLED STUDY; DIABETIC NEUROPATHY; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPATHIC PAIN; OBSERVATIONAL STUDY; PATIENT SATISFACTION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOMNOLENCE;

EID: 84859506421     PISSN: None     EISSN: 18763863     Source Type: Journal    
DOI: 10.2174/1876386301205010001     Document Type: Article

References (49)

1. nd ed. Seattle, Washington: IASP Press 1994; pp. 209-12.
2. Treede RD, Jensen TS, Campbell JN, et al. Redefinition of neuropathic pain and a grading system for clinical use: consensus statement on clinical and research diagnostic criteria. Neurology 2008; 70: 1630-5.
3. Bouhassira D, Lanteri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2008; 136: 380-7.
4. Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain 2006; 7: 281-9.
5. Freynhagen R, Bennett MI. Diagnosis and management of neuropathic pain. BMJ 2009; 339: b3002.
6. Baron R, Binder A. [How neuropathic is sciatica? The mixed pain concept]. Orthopade 2004; 33(5): 568-75.
7. Cherny NI, Thaler HT, Friedlander-Klar H, et al. Opioid responsiveness of cancer pain syndromes caused by neuropathic or nociceptive mechanisms: a combined analysis of controlled, singledose studies. Neurology 1994; 44(5): 857-61.
8. Grond S, Radbruch L, Meuser T, Sabatowski R, Loick G, Lehmann KA. Assessment and treatment of neuropathic cancer pain following WHO guidelines. Pain 1999; 79(1): 15-20.
9. Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care 2008; 31(7): 1448-54.
10. Cappuzzo KA. Treatment of postherpetic neuralgia: focus on pregabalin. Clin Interv Aging 2009; 4: 17-23.
11. Semel D, Murphy TK, Zlateva G, Cheung R, Emir B. Evaluation of the safety and efficacy of pregabalin in older patients with neuropathic pain: results from a pooled analysis of 11 clinical studies. BMC Fam Pract 2010; 11: 85.
12. van Seventer R, Bach FW, Toth CC, et al. Pregabalin in the treatment of post-traumatic peripheral neuropathic pain: a randomized double-blind trial. Eur J Neurol 2010; 17(8): 1082-9.
13. Siddall PJ, Cousins MJ, Otte A, Griesing T, Chambers R, Murphy TK. Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial. Neurology 2006; 67(10): 1792-800.
14. Arnold L, Mease P, Silverman S. Pregabalin: an alpha2-delta (alpha2-delta) ligand for the management of fibromyalgia. Am J Manag Care 2010; 16(5 Suppl): S138-43.
15. Bandelow B, Wedekind D, Leon T. Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention. Expert Rev Neurother 2007; 7(7): 769-81.
16. Beydoun A, Nasreddine W, Atweh S. Efficacy and tolerability of pregabalin in partial epilepsy. Expert Rev Neurother 2008; 8(7): 1013-24.
17. Dooley DJ, Taylor CP, Donevan S, Feltner D. Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission. Trends Pharmacol Sci 2007; 28(2): 75-82.
18. Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta subunit as a target for antiepileptic drug discovery. Epilepsy Res 2007; 73(2): 137-50.
19. Bauer CS, Nieto-Rostro M, Rahman W, et al. The increased trafficking of the calcium channel subunit alpha2delta-1 to presynaptic terminals in neuropathic pain is inhibited by the alpha2delta ligand pregabalin. J Neurosci 2009; 29(13): 4076-88
20. Yuichi T, Keiko T, Hideki O, Mitsuo T. Pregabalin, S-()-3-isobutylgaba, activates the descending noradrenergic system to alleviate neuropathic pain in the mouse partial sciatic nerve ligation model. Neuropharmacology 2007; 53: 842-53.
21. Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet 2010; 49(10): 661-9.
22. Johannessen LC, Patsalos PN. Drug interactions involving the new secondand third-generation antiepileptic drugs. Expert Rev Neurother 2010; 10(1): 119-40.
23. Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010; 85(3 Suppl): S3-14.
24. Attal N, Cruccu G, Baron R, et al. European Federation of Neurological Societies EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010; 17(9): 1113-e88.
25. Bril V, England J, Franklin GM, et al. Evidence-based guideline: Treatment of painful diabetic neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2011; 76(20): 1758-65.
26. Portenoy RK. Treatment of cancer pain. Lancet 2011; 377(9784): 2236-47.
27. Jost L, Roila F, ESMO Guidelines Working Group. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol 2010; 21(Suppl 5): v257-60.
28. European Medicines Agency. Pregabalin summary of product characteristics.
29. Mallison R, Tilke C, Brasser M, Pittrow D. Efficacy and tolerability of pregabalin in patients with neuropathic pain. Observational study under clinical practice conditions. MMW Fortschr Med 2007; 149(14): 46.
30. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989; 28(2): 193-213.
31. Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care 2006; 29(7): 1518-22.
32. Van Acker K, Bouhassira D, De Bacquer D, et al. Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab 2009; 35(3): 206-13.
33. Koes BW, van Tulder MW, Thomas S. Diagnosis and treatment of low back pain. BMJ 2006; 332(7555): 1430-4.
34. Andersson GB. Epidemiological features of chronic low-back pain. Lancet 1999; 354(9178): 581-5.
35. Freynhagen R, Baron R, Gockel U, Tölle TR. Pain DETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006; 22(10): 1911-20.
36. Freynhagen R, Baron R. The evaluation of neuropathic components in low back pain. Curr Pain Headache Rep 2009; 13(3): 185-90.
37. Christo PJ, Mazloomdoost D. Cancer pain and analgesia. Ann N Y Acad Sci 2008; 1138: 278-98.
38. Tölle T, Freynhagen R, Versavel M, Trostmann U, Young JP Jr. Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain 2008; 12(2): 203-13.
39. Navarro A, Saldaña MT, Pérez C, Torrades S, Rejas J. Patientreported outcomes in subjects with neuropathic pain receiving pregabalin: evidence from medical practice in primary care settings. Pain Med 2010; 11 (5): 719-31.
40. Xochilcal MM, Castro EM, Guajardo-Rosas J, et al. A prospective, open-label, multicentre study of pregabalin in the treatment of neuropathic pain in Latin America. Int J Clin Pract 2010; 64(9): 1301-9.
41. Anastassiou E, Iatrou CA, Vlaikidis N, et al. Impact of pregabalin treatment on pain, pain-related sleep interference and general wellbeing in patients with neuropathic pain: a non-interventional, multicentre, post-marketing study. Clin Drug Investig 2011; 31(6): 417-26.
42. Freynhagen R, Grond S, Schüpfer G, et al. Efficacy and safety of pregabalin in treatment refractory patients with various neuropathic pain entities in clinical routine. Int J Clin Pract 2007; 61(12): 1989-96.
43. Lampl C, Schweiger C, Haider B, Lechner A. Pregabalin as mono or add-on therapy for patients with refractory chronic neuropathic pain: a post-marketing prescription-event monitoring study. J Neurol 2010; 257(8): 1265-73.
44. Saldaña MT, Navarro A, Pérez C, Masramón X, Rejas J. Patient-reported-outcomes in subjects with painful lumbar or cervical radiculopathy treated with pregabalin: evidence from medical practice in primary care settings. Rheumatol Int 2010; 30(8): 1005-15.
45. Krystal AD, Roth T. Introduction: Definitions, measurements, and management in insomnia. J Clin Psychiatry 2004; 65(Suppl 8): 5-7.
46. Kyle SD, Morgan K, Espie CA. Insomnia and health-related quality of life. Sleep Med Rev 2010;14(1): 69-82.
47. Pieh C, Popp R, Geisler P, Hajak G. Sleep and pain: a bidirectional relation?. Psychiatr Prax 2011; 38(4): 166-7.
48. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342(25): 1887-92.
49. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000; 342(25): 1878-86.